膀胱灌注吡柔比星与米托蒽醌预防膀胱癌复发的临床疗效和不良反应比较

发布时间：2018-05-26 22:14

本文选题：膀胱肿瘤 + 化学疗法　；参考：《中国新药与临床杂志》2015年03期

【摘要】：目的比较膀胱灌注吡柔比星和米托蒽醌预防膀胱癌复发的临床疗效与不良反应。方法 61例膀胱癌患者分为吡柔比星组(n=30,每次40 mg)和米托蒽醌组(n=31,每次20 mg)。两组患者均按常规方法和间隔时间,经导尿管行膀胱灌注1年,定期行膀胱镜检查,判定有无肿瘤复发。结果随访17~36个月。吡柔比星组和米托蒽醌组复发率分别为17%(5/30)和16%(5/31)。需治疗的不良反应分别为20%(6/30)和23%(7/31)。两组比较疗效及不良反应无显著差异(P0.05)。吡柔比星组出现疼痛性血尿、一过性尿失禁等不良反应较为严重;米托蒽醌组相对较轻,但出现溃疡性膀胱炎2例。结论吡柔比星、米托蒽醌膀胱灌注预防膀胱癌复发疗效相当;但米托蒽醌不良反应较轻,优于吡柔比星。
[Abstract]:Objective to compare the clinical efficacy and adverse reactions of intravesical instillation of pirarubicin and mitoxantrone in the prevention of bladder cancer recurrence. Methods Sixty-one patients with bladder cancer were divided into two groups: 30 cases of pirarubicin group (40 mg / time) and 31 cases of mitoxantrone group (20 mg / time). According to the routine method and interval, the patients in both groups were given bladder instillation for 1 year, and cystoscopy was performed regularly to determine the recurrence of tumor. Results the follow-up was 17 ~ 36 months. The recurrence rates of pirarubicin and mitoxantrone were 17 / 5 / 30 and 16 / 5 / 31, respectively. The adverse reactions needed to be treated were 20 / 6 / 30 and 23 / 7 / 31 / 3 respectively. There was no significant difference in curative effect and adverse reaction between the two groups (P 0.05). The adverse reactions such as painful hematuria, transient urinary incontinence and mitoxantrone group were relatively mild, but 2 cases had ulcerative cystitis. Conclusion the efficacy of intravesical instillation of Pirarubicin and mitoxantrone in the prevention of recurrence of bladder cancer is similar, but mitoxantrone adverse reaction is mild and superior to that of imirubicin.
【作者单位】：连云港市第二人民医院药学部;连云港市第二人民医院泌尿外科;连云港市中医院;南京中医药大学附属连云港医院泌尿外科;
【分类号】：R737.14

【参考文献】